Biotech Values

[DewDiligence]

>SGP VRTX – Could very well be that the FDA required 28 week treatment [in the SPRINT-2 treatment-naïve trial] and it will juxtapose against 48 week treatment given the present data out of boceprevir.<

Regardless of whether the FDA required a 28-week arm in SPRINT-2, it clearly benefits SGP to include such an arm.